Filtered By:
Cancer: Lymphoma
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 25370 results found since Jan 2013.
Childhood Burkitt Lymphoma in Nigeria
Clin J Oncol Nurs. 2023 Sep 15;27(5):571-574. doi: 10.1188/23.CJON.571-574.ABSTRACTBurkitt lymphoma (BL) is a curable, aggressive pediatric cancer, yet in low- and middle-income countries like Nigeria, children with BL face poor survival outcomes. Identifying barriers to and facilitators of cancer care for.PMID:37729460 | DOI:10.1188/23.CJON.571-574
Source: Clinical Journal of Oncology Nursing - September 20, 2023 Category: Nursing Authors: Ijeoma Julie Eche-Ugwu Source Type: research
Nursing Alchemy: Transforming R-CHOP Information Into Essentials
Clin J Oncol Nurs. 2023 Sep 15;27(5):553-564. doi: 10.1188/23.CJON.553-564.ABSTRACTA combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is a first-line combination chemotherapy regimen for diffuse large B-cell lymphoma that has many nursing implications. Understand.PMID:37729458 | DOI:10.1188/23.CJON.553-564
Source: Clinical Journal of Oncology Nursing - September 20, 2023 Category: Nursing Authors: Alexandra K Sakowski Puja R Patel Source Type: research
Early T-Cell Precursor Leukemia: A High-Risk Subtype of Acute Lymphoblastic Leukemia, Single Center Experience in Jordan
CONCLUSION: ETP-ALL/LBL represents a high-risk disease subtype of adult ALL. Novel treatment strategies are needed to improve treatment outcomes in this patient's population.PMID:37730482 | DOI:10.1016/j.clml.2023.08.007
Source: Clinical Lymphoma and Myeloma - September 20, 2023 Category: Cancer & Oncology Authors: Khalid Halahleh Isra Muradi Mohammad Zakaria Khalil Lina Halahleh Maher Sughayer Nazmi Kamal Iyad Sultan Kamal Alrabi Source Type: research
Early Mortality as a Quality Indicator in Frontline and Salvage Acute Myeloid Leukemia
CONCLUSIONS: Quality measure algorithms should incorporate a risk mortality index related to leukemia vs. other tumors and benign conditions and a risk mortality index related to the treatment status of leukemia (salvage vs. frontline therapy).PMID:37730483 | DOI:10.1016/j.clml.2023.08.016
Source: Clinical Lymphoma and Myeloma - September 20, 2023 Category: Cancer & Oncology Authors: Koji Sasaki Farhad Ravandi Courtney DiNardo Mary Alma Welch Tapan Kadia Hagop Kantarjian Source Type: research
Early T-Cell Precursor Leukemia: A High-Risk Subtype of Acute Lymphoblastic Leukemia, Single Center Experience in Jordan
CONCLUSION: ETP-ALL/LBL represents a high-risk disease subtype of adult ALL. Novel treatment strategies are needed to improve treatment outcomes in this patient's population.PMID:37730482 | DOI:10.1016/j.clml.2023.08.007
Source: Clinical Lymphoma and Myeloma - September 20, 2023 Category: Cancer & Oncology Authors: Khalid Halahleh Isra Muradi Mohammad Zakaria Khalil Lina Halahleh Maher Sughayer Nazmi Kamal Iyad Sultan Kamal Alrabi Source Type: research
Synchronous rectal adenocarcinoma and intestinal mantle cell lymphoma: A case report
CONCLUSION: Synchronous rectal adenocarcinoma and intestinal MCL presenting as multiple lymphomatous polyposis are extremely rare. MCL is often discovered fortuitously when rectal cancer is diagnosed. The coexistence of these tumors poses treatment challenges.PMID:37727717 | PMC:PMC10506007 | DOI:10.12998/wjcc.v11.i24.5772
Source: Clinical Colorectal Cancer - September 20, 2023 Category: Cancer & Oncology Authors: Kim-Van Vu Nguyen-Van Trong Nguyen-Thi Khuyen Do Huyen Nga Hoang Anh Nguyen Tien Trung Pham Trung Thong Nguyen Minh Duc Source Type: research
Targeted therapy and immunotherapy for orbital and periorbital tumors: a major review
This article will focus on recent updates in the application of available targeted and immunotherapy for managing orbital and periorbital tumors and tumor-like conditions, which include cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, cutaneous melanoma, Merkel cell carcinoma, sebaceous gland carcinoma, solitary fibrous tumor, dermatofibrosarcoma protuberans, orbital meningioma, neurofibromatosis, Langerhans cell histiocytosis, ocular adnexal lymphoma, orbital lymphatic malformation, and adenoid cystic carcinoma.PMID:37728602 | DOI:10.1080/01676830.2023.2256848
Source: Orbit - September 20, 2023 Category: Opthalmology Authors: Emmanuel Lee Boniao Richard C Allen Gangadhara Sundar Source Type: research
Cancers, Vol. 15, Pages 4651: Is Insulin Receptor Substrate4 (IRS4) a Platform Involved in the Activation of Several Oncogenes?
Miguel A. Ortega
The IRS (insulin receptor substrate) family of scaffold proteins includes insulin receptor substrate-4 (IRS4), which is expressed only in a few cell lines, including human kidney, brain, liver, and thymus and some cell lines. Its N-terminus carries a phosphotyrosine-binding (PTB) domain and a pleckstrin homology domain (PH), which distinguishes it as a member of this family. In this paper, we collected data about the molecular mechanisms that explain the relevance of IRS4 in the development of cancer and identify IRS4 differences that distinguish it from IRS1 and IRS2. Search engines and different dat...
Source: Cancers - September 20, 2023 Category: Cancer & Oncology Authors: Luis G. Guijarro Francisco Javier Justo Bermejo Diego Liviu Boaru Patricia De Castro-Martinez Diego De Leon-Oliva Oscar Fraile-Mart ínez Cielo Garcia-Montero Melchor Alvarez-Mon Mar ía del Val Toledo-Lobo Miguel A. Ortega Tags: Review Source Type: research
LC-MS/MS methods for determination of venetoclax in human plasma and cerebrospinal fluid
Biomed Chromatogr. 2023 Sep 18:e5738. doi: 10.1002/bmc.5738. Online ahead of print.ABSTRACTWe developed and validated sensitive MS/MS methods for the determination of venetoclax, an oral selective B-cell lymphoma-2 inhibitor, in human plasma and cerebrospinal fluid (CSF). Acetonitrile was used as protein precipitant. The mobile phase was 10 mM ammonium formate consisting of 0.1% formic acid and acetonitrile (40:60, v/v). The analytes were separated on an ACQUITY UPLC HSS T3 column (2.1 × 50 mm, 1.8 μm) in 5 min. An API 4000 mass spectrometer was selected to quantify venetoclax and internal standard using m/z 868.3 → 63...
Source: Biomedical Chromatography : BMC - September 19, 2023 Category: Biomedical Science Authors: Yan-Ling Yang Zhou-Yi Qian Yang Zhao Xiang-Long Chen Qiong-Ye Huang Yu-Jiao Guo Lu-Ning Sun Yong-Qing Wang Source Type: research
Recent Advances in Nanobiotechnology for the Treatment of Non-Hodgkin's Lymphoma
Mini Rev Med Chem. 2023 Sep 15. doi: 10.2174/1389557523666230915103121. Online ahead of print.ABSTRACTLymphoma is the eighth most common type of cancer worldwide. Currently, lymphoma is mainly classified into two main groups: Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL), with NHL accounting for 80% to 90% of the cases. NHL is primarily divided into B, T, and natural killer (NK) cell lymphoma. Nanotechnology is developing rapidly and has made significant contributions to the field of medicine. This review summarizes the advancements of nanobiotechnology in recent years and its applications in the treatment of NH...
Source: Mini Reviews in Medicinal Chemistry - September 19, 2023 Category: Chemistry Authors: Shuxian Liu Minghao Xu Lei Zhong Xiangmin Tong Suying Qian Source Type: research
Integration of genomic sequencing drives therapeutic targeting of PDGFRA in T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma
CONCLUSIONS: Refractory T-ALL has not been fully characterized. Alterations in PDGFRA or other targetable kinases may inform therapy for patients with refractory T-ALL who otherwise have limited treatment options. Clinical genomic profiling, in real time, is needed for fully informed therapeutic decision making.PMID:37725576 | DOI:10.1158/1078-0432.CCR-22-2562
Source: Cell Research - September 19, 2023 Category: Cytology Authors: Jonathan Paolino Boris Dimitrov Beth Apsel Winger Angelica Sandoval-Perez Amith Vikram Rangarajan Nicole Ocasio-Martinez Harrison K Tsai Yuting Li Amanda L Robichaud Delan Khalid Charlie Hatton Riaz Gillani Petri Polonen Anthony Dilig Giacomo Gotti Julia Source Type: research
Recent Advances in Nanobiotechnology for the Treatment of Non-Hodgkin's Lymphoma
Mini Rev Med Chem. 2023 Sep 15. doi: 10.2174/1389557523666230915103121. Online ahead of print.ABSTRACTLymphoma is the eighth most common type of cancer worldwide. Currently, lymphoma is mainly classified into two main groups: Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL), with NHL accounting for 80% to 90% of the cases. NHL is primarily divided into B, T, and natural killer (NK) cell lymphoma. Nanotechnology is developing rapidly and has made significant contributions to the field of medicine. This review summarizes the advancements of nanobiotechnology in recent years and its applications in the treatment of NH...
Source: Mini Reviews in Medicinal Chemistry - September 19, 2023 Category: Chemistry Authors: Shuxian Liu Minghao Xu Lei Zhong Xiangmin Tong Suying Qian Source Type: research
Integration of genomic sequencing drives therapeutic targeting of PDGFRA in T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma
CONCLUSIONS: Refractory T-ALL has not been fully characterized. Alterations in PDGFRA or other targetable kinases may inform therapy for patients with refractory T-ALL who otherwise have limited treatment options. Clinical genomic profiling, in real time, is needed for fully informed therapeutic decision making.PMID:37725576 | DOI:10.1158/1078-0432.CCR-22-2562
Source: Clinical Cancer Research - September 19, 2023 Category: Cancer & Oncology Authors: Jonathan Paolino Boris Dimitrov Beth Apsel Winger Angelica Sandoval-Perez Amith Vikram Rangarajan Nicole Ocasio-Martinez Harrison K Tsai Yuting Li Amanda L Robichaud Delan Khalid Charlie Hatton Riaz Gillani Petri Polonen Anthony Dilig Giacomo Gotti Julia Source Type: research
LC-MS/MS methods for determination of venetoclax in human plasma and cerebrospinal fluid
Biomed Chromatogr. 2023 Sep 18:e5738. doi: 10.1002/bmc.5738. Online ahead of print.ABSTRACTWe developed and validated sensitive MS/MS methods for the determination of venetoclax, an oral selective B-cell lymphoma-2 inhibitor, in human plasma and cerebrospinal fluid (CSF). Acetonitrile was used as protein precipitant. The mobile phase was 10 mM ammonium formate consisting of 0.1% formic acid and acetonitrile (40:60, v/v). The analytes were separated on an ACQUITY UPLC HSS T3 column (2.1 × 50 mm, 1.8 μm) in 5 min. An API 4000 mass spectrometer was selected to quantify venetoclax and internal standard using m/z 868.3 → 63...
Source: Biomedical Chromatography : BMC - September 19, 2023 Category: Biomedical Science Authors: Yan-Ling Yang Zhou-Yi Qian Yang Zhao Xiang-Long Chen Qiong-Ye Huang Yu-Jiao Guo Lu-Ning Sun Yong-Qing Wang Source Type: research
